

Clive Ballard

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7191909/clive-ballard-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

499
papers

35,008
citations

87
h-index

178
g-index

563
ext. papers

43,729
ext. citations

6.7
avg, IF

7.24
L-index

#	Paper	IF	Citations
499	Dementia prevention, intervention, and care. <i>Lancet, The</i> , 2017 , 390, 2673-2734	40	2763
498	Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. <i>Lancet Psychiatry, the</i> , 2020 , 7, 547-560	23.3	2516
497	Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. <i>Neurology</i> , 2017 , 89, 88-100	6.5	1691
496	Alzheimer's disease. <i>Lancet, The</i> , 2011 , 377, 1019-31	40	1645
495	Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. <i>Lancet, The</i> , 2020 , 396, 413-446	40	1387
494	Vascular cognitive impairment. <i>Lancet Neurology, The</i> , 2003 , 2, 89-98	24.1	970
493	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology, The</i> , 2016 , 15, 455-532	24.1	921
492	Putting brain training to the test. <i>Nature</i> , 2010 , 465, 775-8	50.4	709
491	Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2014 , 383, 533-40	40	519
490	Donepezil and memantine for moderate-to-severe Alzheimer's disease. <i>New England Journal of Medicine</i> , 2012 , 366, 893-903	59.2	483
489	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 217-231	15	458
488	The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. <i>Lancet Neurology, The</i> , 2009 , 8, 151-7	24.1	434
487	Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. <i>BMJ, The</i> , 2011 , 343, d4065	5.9	371
486	Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. <i>Lancet Neurology, The</i> , 2009 , 8, 613-8	24.1	358
485	Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2011 , 378, 403-11	40	348
484	Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. <i>Lancet Neurology, The</i> , 2012 , 11, 697-707	24.1	342
483	Depression in Parkinson disease--epidemiology, mechanisms and management. <i>Nature Reviews Neurology</i> , 2011 , 8, 35-47	15	338

482	Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. <i>BMJ, The</i> , 2006 , 332, 756-61	5.9	334
481	Incidence and prediction of falls in dementia: a prospective study in older people. <i>PLoS ONE</i> , 2009 , 4, e5521	3.7	298
480	Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. <i>Annals of Neurology</i> , 2005 , 58, 773-6	9.4	280
479	A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16, 528-36	3.9	266
478	Management of agitation and aggression associated with Alzheimer disease. <i>Nature Reviews Neurology</i> , 2009 , 5, 245-55	15	260
477	Management of behavioral problems in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2010 , 22, 346-72	3.4	251
476	Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 553-8	4.6	250
475	Cholinesterases: roles in the brain during health and disease. <i>Current Alzheimer Research</i> , 2005 , 2, 307-18		246
474	Donepezil for the treatment of agitation in Alzheimer's disease. <i>New England Journal of Medicine</i> , 2007 , 357, 1382-92	59.2	240
473	Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial. <i>Pharmacology Biochemistry and Behavior</i> , 2003 , 75, 651-9	3.9	234
472	Neuropsychiatric symptoms in Alzheimer's disease: past progress and anticipation of the future. <i>Alzheimeris and Dementia</i> , 2013 , 9, 602-8	1.2	215
471	Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. <i>BMJ, The</i> , 2005 , 330, 874	5.9	215
470	Towards defining the neuropathological substrates of vascular dementia. <i>Journal of the Neurological Sciences</i> , 2004 , 226, 75-80	3.2	215
469	Assessment and treatment of pain in people with dementia. <i>Nature Reviews Neurology</i> , 2012 , 8, 264-74	15	207
468	Neuroleptic drugs in dementia: benefits and harm. <i>Nature Reviews Neuroscience</i> , 2006 , 7, 492-500	13.5	202
467	Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. <i>Journal of Neurochemistry</i> , 1999 , 73, 1590-7	6	195
466	Drug repositioning for Alzheimer's disease. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 833-46	64.1	191
465	Prevalence and severity of gait disorders in Alzheimer's and non-Alzheimer's dementias. <i>Journal of the American Geriatrics Society</i> , 2005 , 53, 1681-7	5.6	180

464	A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease. <i>primary care companion for CNS disorders, The, 2013, 15,</i>	1.2	174
463	Non-pharmacological interventions in dementia. <i>Advances in Psychiatric Treatment, 2004, 10, 171-177</i>		169
462	Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. <i>Journal of Clinical Psychiatry, 2008, 69, 341-8</i>	4.6	167
461	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology, 2017, 13, 81-95</i>	15	165
460	Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. <i>Journal of Alzheimer's Disease, 2019, 67, 779-794</i>	4.3	163
459	Optimised anaesthesia to reduce post operative cognitive decline (POCD) in older patients undergoing elective surgery, a randomised controlled trial. <i>PLoS ONE, 2012, 7, e37410</i>	3.7	160
458	Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. <i>Lancet, The, 1998, 351, 1032-3</i>	4.0	158
457	Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 440-449</i>	6	153
456	CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. <i>Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1080-6</i>	5.5	151
455	A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. <i>European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 615-22</i>	8.8	151
454	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. <i>Neurology, 2020, 94, 743-755</i>	5.5	151
453	Prospective follow-up study between 3 and 15 months after stroke: improvements and decline in cognitive function among dementia-free stroke survivors >75 years of age. <i>Stroke, 2003, 34, 2440-4</i>	6.7	148
452	Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. <i>Annals of Neurology, 2000, 48, 868-876</i>	9.4	147
451	Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. <i>European Journal of Pharmacology, 2000, 393, 215-22</i>	5.3	147
450	Frequency and case identification of dementia with Lewy bodies using the revised consensus criteria. <i>Dementia and Geriatric Cognitive Disorders, 2008, 26, 445-52</i>	2.6	145
449	A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). <i>PLoS Medicine, 2008, 5, e76</i>	11.6	144
448	Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 160-5</i>	5.5	143
447	Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. <i>Alzheimer Disease and Associated Disorders, 2009, 23, 295-7</i>	2.5	142

446	Hypertension is a potential risk factor for vascular dementia: systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 661-9	3.9	137
445	Endogenous neurogenesis in the human brain following cerebral infarction. <i>Regenerative Medicine</i> , 2007 , 2, 69-74	2.5	137
444	Is physical activity a potential preventive factor for vascular dementia? A systematic review. <i>Aging and Mental Health</i> , 2010 , 14, 386-95	3.5	131
443	Improving quality of life for people with dementia in care homes: making psychosocial interventions work. <i>British Journal of Psychiatry</i> , 2012 , 201, 344-51	5.4	126
442	Dementia in Down's syndrome. <i>Lancet Neurology, The</i> , 2016 , 15, 622-36	24.1	125
441	Quality of life for people with dementia living in residential and nursing home care: the impact of performance on activities of daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs. <i>International Psychogeriatrics</i> , 2001 , 13, 93-106	3.4	124
440	Altered neurogenesis in Alzheimer's disease. <i>Journal of Psychosomatic Research</i> , 2006 , 61, 311-6	4.1	120
439	The pattern of cognitive performance in CADASIL: a monogenic condition leading to subcortical ischemic vascular dementia. <i>American Journal of Psychiatry</i> , 2005 , 162, 2078-85	11.9	120
438	Neurogenic abnormalities in Alzheimer's disease differ between stages of neurogenesis and are partly related to cholinergic pathology. <i>Neurobiology of Disease</i> , 2012 , 47, 155-62	7.5	117
437	The prognosis of dementia with Lewy bodies. <i>Lancet Neurology, The</i> , 2017 , 16, 390-398	24.1	116
436	Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2012 , 379, 528-36	4.0	116
435	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. <i>Brain Pathology</i> , 2015 , 25, 401-8	6	115
434	Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. <i>PLoS ONE</i> , 2012 , 7, e35185	3.7	113
433	The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review. <i>International Psychogeriatrics</i> , 2014 , 26, 1083-98	3.4	109
432	Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. <i>American Journal of Psychiatry</i> , 2004 , 161, 843-9	11.9	109
431	A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 631-6	4.6	109
430	The response of agitated behavior to pain management in persons with dementia. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 708-17	6.5	106
429	An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. <i>Psychopharmacology</i> , 2008 , 198, 127-39	4.7	106

428	White matter hyperintensities are associated with impairment of memory, attention, and global cognitive performance in older stroke patients. <i>Stroke</i> , 2004 , 35, 1270-5	6.7	103
427	A double-blind placebo-controlled randomized trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 31, 158-64	2.6	102
426	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology</i> , 2015 , 14, 1171-81	24.1	101
425	Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2004 , 19, 371-7	3.9	101
424	Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. <i>Brain</i> , 2018 , 141, 582-595	11.2	100
423	A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 114-9	4.6	100
422	Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. <i>Lancet Neurology</i> , 2018 , 17, 213-222	24.1	99
421	The Effect of an Online Cognitive Training Package in Healthy Older Adults: An Online Randomized Controlled Trial. <i>Journal of the American Medical Directors Association</i> , 2015 , 16, 990-7	5.9	96
420	Determining the minimum clinically important differences for outcomes in the DOMINO trial. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 812-7	3.9	96
419	Dementia Care Mapping as a research tool for measuring quality of life in care settings: psychometric properties. <i>International Journal of Geriatric Psychiatry</i> , 2002 , 17, 1064-70	3.9	96
418	Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 35-43	4.1	95
417	Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 130-142	27.4	92
416	Dementia with Lewy bodies. <i>Seminars in Clinical Neuropsychiatry</i> , 2003 , 8, 46-57		92
415	Guidelines for the management of agitation in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16, 714-7	3.9	90
414	Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial. <i>PLoS Medicine</i> , 2018 , 15, e1002500	11.6	89
413	Management of behavioral and psychological symptoms in people with Alzheimer's disease: an international Delphi consensus. <i>International Psychogeriatrics</i> , 2019 , 31, 83-90	3.4	87
412	Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. <i>Alzheimer's and Dementia</i> , 2016 , 12, 1149-1158	1.2	86
411	Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2019 , 27, 823-834	6.5	85

410	Management of neuropsychiatric symptoms in people with dementia. <i>CNS Drugs</i> , 2010 , 24, 729-39	6.7	85
409	Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. <i>American Journal of Psychiatry</i> , 2000 , 157, 1682-4	11.9	85
408	The disconnect between evidence and practice: a systematic review of person-centred interventions and training manuals for care home staff working with people with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2014 , 29, 797-807	3.9	83
407	Medial temporal atrophy rather than white matter hyperintensities predict cognitive decline in stroke survivors. <i>Neurobiology of Aging</i> , 2007 , 28, 1664-9	5.6	80
406	Impact of Antipsychotic Review and Nonpharmacological Intervention on Antipsychotic Use, Neuropsychiatric Symptoms, and Mortality in People With Dementia Living in Nursing Homes: A Factorial Cluster-Randomized Controlled Trial by the Well-Being and Health for People With Dementia (WHELD) Program. <i>American Journal of Psychiatry</i> , 2016 , 173, 252-62	11.9	79
405	Autonomic function is impaired in elderly stroke survivors. <i>Stroke</i> , 2005 , 36, 1026-30	6.7	78
404	Regulation of attention and response to therapy in dementia by butyrylcholinesterase. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 231-9		78
403	The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999 , 10, 97-103	2.6	75
402	Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. <i>Neurobiology of Aging</i> , 2014 , 35, 2836-2844	5.6	74
401	Identification of novel Bsynuclein isoforms in human brain tissue by using an online nanoLC-ESI-FTICR-MS method. <i>Neurochemical Research</i> , 2011 , 36, 2029-42	4.6	74
400	Neuropsychiatric symptoms in dementia: importance and treatment considerations. <i>International Review of Psychiatry</i> , 2008 , 20, 396-404	3.6	74
399	Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. <i>Archives of Neurology</i> , 1999 , 56, 961-5		74
398	Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. <i>Current Opinion in Psychiatry</i> , 2009 , 22, 532-40	4.9	73
397	Language impairment in dementia: impact on symptoms and care needs in residential homes. <i>International Journal of Geriatric Psychiatry</i> , 2003 , 18, 1002-6	3.9	71
396	Agitation and aggression in people with Alzheimer's disease. <i>Current Opinion in Psychiatry</i> , 2013 , 26, 252-9	4.9	70
395	Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity. <i>Brain</i> , 2006 , 129, 1780-8	11.2	70
394	Profile of neuropsychological deficits in older stroke survivors without dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003 , 16, 52-6	2.6	69
393	Association between mild vascular cognitive impairment and impaired activities of daily living in older stroke survivors without dementia. <i>Journal of the American Geriatrics Society</i> , 2005 , 53, 103-7	5.6	65

392	Systematic review of services providing information and/or advice to people with dementia and/or their caregivers. <i>International Journal of Geriatric Psychiatry</i> , 2012 , 27, 628-36	3.9	64
391	Early and presenting symptoms of dementia with lewy bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 32, 202-8	2.6	62
390	Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2020 , 77, 164-174	17.2	62
389	Neurocardiovascular instability, hypotensive episodes, and MRI lesions in neurodegenerative dementia. <i>Annals of the New York Academy of Sciences</i> , 2000 , 903, 442-5	6.5	61
388	The effect of staff training on agitation and use of restraint in nursing home residents with dementia: a single-blind, randomized controlled trial. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 80-6	4.6	59
387	Current prevalence of dementia, depression and behavioural problems in the older adult care home sector: the South East London Care Home Survey. <i>Age and Ageing</i> , 2014 , 43, 562-7	3	57
386	Impact of Behavioral and Psychological Symptoms of Dementia on Caregivers. <i>International Psychogeriatrics</i> , 2000 , 12, 93-105	3.4	57
385	Diagnosing dementia with Lewy bodies. <i>Lancet, The</i> , 1999 , 354, 1227-8	4.0	57
384	Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial). <i>American Journal of Geriatric Psychiatry</i> , 2009 , 17, 726-33	6.5	56
383	Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. <i>Behavioural Brain Research</i> , 2005 , 161, 299-305	3.4	56
382	Lewy body disease: thalamic cholinergic activity related to dementia and parkinsonism. <i>Neurobiology of Aging</i> , 2006 , 27, 433-8	5.6	56
381	Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. <i>Consciousness and Cognition</i> , 2002 , 11, 461-74	2.6	55
380	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 47	51.1	55
379	A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy bodies and Alzheimer's disease. <i>International Psychogeriatrics</i> , 1997 , 9, 381-8	3.4	54
378	Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. <i>Neurology</i> , 2007 , 69, S23-8	6.5	54
377	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020 , 16, 265-284	15	53
376	The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 1030-8	3.9	53
375	Factors influencing the prescribing of medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative study. <i>Age and Ageing</i> , 2008 , 37, 547-52	3	53

374	Stroke and cognition. <i>Current Atherosclerosis Reports</i> , 2001 , 3, 334-9	6	53
373	Stage-specific changes in neurogenic and glial markers in Alzheimer's disease. <i>Biological Psychiatry</i> , 2015 , 77, 711-9	7.9	52
372	Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 1139-1152	4.3	52
371	Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2006 , 21, 50-6	7.5	52
370	Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 325-331	5.5	51
369	Don't use antipsychotics routinely to treat agitation and aggression in people with dementia. <i>BMJ, The</i> , 2014 , 349, g6420	5.9	51
368	Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity. <i>International Psychogeriatrics</i> , 2009 , 21, 216-9	3.4	51
367	Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 321-31	6.5	50
366	Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2015 , 30, 46-54	3.9	49
365	The prevalence of autonomic symptoms in dementia and their association with physical activity, activities of daily living and quality of life. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006 , 22, 230-7	2.6	49
364	Involvement of alpha6/alpha3 neuronal nicotinic acetylcholine receptors in neuropsychiatric features of Dementia with Lewy bodies: [(125)I]-alpha-conotoxin MII binding in the thalamus and striatum. <i>Neuroscience Letters</i> , 2004 , 372, 220-5	3.3	49
363	Psychotic symptoms in patients with dementia. <i>International Journal of Geriatric Psychiatry</i> , 1995 , 10, 743-752	3.9	49
362	Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency. <i>Movement Disorders</i> , 2016 , 31, 352-9	7	49
361	Treatment of behavioral and psychological symptoms of Alzheimer's disease. <i>Current Treatment Options in Neurology</i> , 2012 , 14, 113-25	4.4	48
360	Loneliness, physical activity, and mental health during COVID-19: a longitudinal analysis of depression and anxiety in adults over the age of 50 between 2015 and 2020. <i>International Psychogeriatrics</i> , 2021 , 33, 505-514	3.4	48
359	A roadmap to advance dementia research in prevention, diagnosis, intervention, and care by 2025. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 900-906	3.9	46
358	Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002 , 14, 167-75	2.6	46
357	Update on Vascular Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016 , 29, 281-301	3.8	46

356	Epidemiology of Pain in People With Dementia Living in Care Homes: Longitudinal Course, Prevalence, and Treatment Implications. <i>Journal of the American Medical Directors Association</i> , 2017 , 18, 453.e1-453.e6	5.9	45
355	Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1797-810	4	44
354	High prevalence of orthostatic hypotension in mild dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009 , 28, 307-13	2.6	44
353	Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities. <i>International Journal of Geriatric Psychiatry</i> , 2002 , 17, 140-5	3.9	44
352	Drug repositioning and repurposing for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2020 , 16, 661-673	15	44
351	A role for APP in Wnt signalling links synapse loss with β amyloid production. <i>Translational Psychiatry</i> , 2018 , 8, 179	8.6	44
350	Associations between cognitively stimulating leisure activities, cognitive function and age-related cognitive decline. <i>International Journal of Geriatric Psychiatry</i> , 2015 , 30, 422-30	3.9	43
349	Course of neuropsychiatric symptoms in dementia: 5-year longitudinal study. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 1361-1369	3.9	43
348	Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 289-98	1.9	43
347	End-of-life care and dementia. <i>Reviews in Clinical Gerontology</i> , 2005 , 15, 135-148		43
346	Long-term mortality in a cohort of home-dwelling elderly with mild Alzheimer's disease and Lewy body dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014 , 38, 161-9	2.6	42
345	New and emerging treatments for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2012 , 12, 535-43	4.3	42
344	Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot 'Prevention of Decline in Cognition after Stroke Trial' (PODCAST) Randomised Controlled Trial. <i>PLoS ONE</i> , 2017 , 12, e0164608	3.7	41
343	The characterisation and impact of 'fluctuating' cognition in dementia with Lewy bodies and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16, 494-8	3.9	41
342	Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study. <i>BMJ Open</i> , 2016 , 6, e010357	3	41
341	Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 559-63	2.6	40
340	Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment. <i>Expert Review of Neurotherapeutics</i> , 2005 , 5, 101-6	4.3	39
339	Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 512-519	5.5	38

338	COSMOS--improving the quality of life in nursing home patients: protocol for an effectiveness-implementation cluster randomized clinical hybrid trial. <i>Implementation Science</i> , 2015 , 10, 131	8.4	38
337	Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. <i>BMJ Open</i> , 2014 , 4, e005158	3	38
336	CSF amyloid β 8 as a novel diagnostic marker for dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 160-4	5.5	38
335	Depressive symptoms in Alzheimer's disease and lewy body dementia: a one-year follow-up study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 32, 143-9	2.6	38
334	ANXIETY DISORDERS IN DEMENTIA SUFFERERS 1996 , 11, 987-990		38
333	A consensus guideline for antipsychotic drug use for dementia in care homes. Bridging the gap between scientific evidence and clinical practice. <i>International Psychogeriatrics</i> , 2015 , 27, 1849-59	3.4	37
332	Hyperintensities and fronto-subcortical atrophy on MRI are substrates of mild cognitive deficits after stroke. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003 , 16, 113-8	2.6	37
331	Profile of mild behavioral impairment and factor structure of the Mild Behavioral Impairment Checklist in cognitively normal older adults. <i>International Psychogeriatrics</i> , 2020 , 32, 705-717	3.4	37
330	Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. <i>PLoS ONE</i> , 2017 , 12, e0179521	3.7	36
329	Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: pathophysiology, clinical features, and pharmacological management. <i>Drugs and Aging</i> , 2013 , 30, 603-11	4.7	36
328	DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. <i>Trials</i> , 2009 , 10, 57	2.8	36
327	Neuroimaging for Lewy body disease: is the in vivo molecular imaging of β ynuclein neuropathology required and feasible?. <i>Brain Research Reviews</i> , 2010 , 65, 28-55		35
326	Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. <i>Journal of the American Medical Directors Association</i> , 2015 , 16, 898.e1-7	5.9	34
325	FITS into practice: translating research into practice in reducing the use of anti-psychotic medication for people with dementia living in care homes. <i>Aging and Mental Health</i> , 2016 , 20, 709-18	3.5	34
324	Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. <i>British Journal of Psychiatry</i> , 2013 , 202, 121-8	5.4	34
323	Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 330-8	2.6	34
322	Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. <i>Pharmaceuticals</i> , 2013 , 6, 1304-21	5.2	33
321	Treatment of dementia with Lewy bodies and Parkinson's disease dementia. <i>Drugs and Aging</i> , 2011 , 28, 769-77	4.7	33

320	Cognitive impairment in depression is not associated with neuropathologic evidence of increased vascular or Alzheimer-type pathology. <i>Biological Psychiatry</i> , 2001 , 49, 130-6	7.9	33
319	The prevalence of depression in the carers of dementia sufferers. <i>International Journal of Geriatric Psychiatry</i> , 1995 , 10, 237-242	3.9	33
318	The individual course of neuropsychiatric symptoms in people with Alzheimer's and Lewy body dementia: 12-year longitudinal cohort study. <i>British Journal of Psychiatry</i> , 2020 , 216, 43-48	5.4	33
317	Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD-a factorial cluster randomised controlled trial. <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 1094-1103	3.9	32
316	Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 1205-1216	3.9	32
315	Choline acetyltransferase activity in vascular dementia and stroke. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009 , 28, 233-8	2.6	32
314	Unfolded protein response is activated in Lewy body dementias. <i>Neuropathology and Applied Neurobiology</i> , 2016 , 42, 352-65	5.2	32
313	Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis: A meta-analysis of longitudinal studies. <i>Ageing Research Reviews</i> , 2019 , 50, 72-80	12	32
312	Utility, reliability, sensitivity and validity of an online test system designed to monitor changes in cognitive function in clinical trials. <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, e83-e92	3.9	31
311	BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. <i>Movement Disorders</i> , 2009 , 24, 392-400	7	31
310	A failure of 'pop-out' in visual search tasks in dementia with Lewy Bodies as compared to Alzheimer's and Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2004 , 19, 763-72	3.9	31
309	The Effect of a Multicomponent Intervention on Quality of Life in Residents of Nursing Homes: A Randomized Controlled Trial (COSMOS). <i>Journal of the American Medical Directors Association</i> , 2019 , 20, 330-339	5.9	31
308	Depression and synaptic zinc regulation in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia. <i>American Journal of Geriatric Psychiatry</i> , 2015 , 23, 141-8	6.5	30
307	Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome. <i>Neurobiology of Aging</i> , 2014 , 35, 1513.e1-5	5.6	30
306	Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome. <i>Neurobiology of Aging</i> , 2013 , 34, 2441.e1-5	5.6	30
305	Synaptic proteins in CSF relate to Parkinson's disease stage markers. <i>Npj Parkinsons Disease</i> , 2017 , 3, 7	9.7	30
304	Depression in the carers of dementia sufferers: a comparison of the carers of patients suffering from dementia with Lewy bodies and the carers of patients with Alzheimer's disease. <i>Journal of Affective Disorders</i> , 2000 , 59, 61-5	6.6	30
303	Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 143-152	5.2	29

302	The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study. <i>CNS Drugs</i> , 2016 , 30, 1097-1109	6.7	29
301	Cortical changes associated with depression and antidepressant use in Alzheimer and Lewy body dementia: an MRI surface-based morphometric study. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 4-13.e1	6.5	29
300	Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. <i>American Journal of Geriatric Psychiatry</i> , 2007 , 15, 435-7	6.5	29
299	Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. <i>Journal of Neural Transmission</i> , 2008 , 115, 869-78	4.3	29
298	Subtle attentional deficits in the absence of dementia are associated with an increased risk of post-operative delirium. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007 , 23, 390-4	2.6	29
297	A positive association between 5HT re-uptake binding sites and depression in dementia with Lewy bodies. <i>Journal of Affective Disorders</i> , 2002 , 69, 219-23	6.6	29
296	Aromatherapy in dementia. <i>Advances in Psychiatric Treatment</i> , 2004 , 10, 296-300		29
295	Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cough? Argument. <i>International Psychogeriatrics</i> , 2005 , 17, 4-12; discussion 22-9	3.4	29
294	Transferrin gene polymorphism in Alzheimer's disease and dementia with Lewy bodies in humans. <i>Neuroscience Letters</i> , 2002 , 317, 13-6	3.3	29
293	Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018 , 177, 232-241	3.5	28
292	Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. <i>Brain</i> , 2009 , 132, 1858-65	11.2	28
291	Amyloid beta concentrations in older people with Down syndrome and dementia. <i>Neuroscience Letters</i> , 2009 , 451, 162-4	3.3	28
290	A prospective study of psychotic symptoms in dementia sufferers: psychosis in dementia. <i>International Psychogeriatrics</i> , 1997 , 9, 57-64	3.4	28
289	Early discriminatory diagnosis of dementia with Lewy bodies. The emerging role of CSF and imaging biomarkers. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 195-205	2.6	28
288	Mental health of people living with dementia in care homes during COVID-19 pandemic. <i>International Psychogeriatrics</i> , 2020 , 32, 1253-1254	3.4	27
287	Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 1054-61	3.9	27
286	Pharmacological profile of an essential oil derived from <i>Melissa officinalis</i> with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2008 , 60, 377-84	4.8	27
285	Functional cognitive disorder: dementia's blind spot. <i>Brain</i> , 2020 , 143, 2895-2903	11.2	27

284	Protocol for the IDEAL-2 longitudinal study: following the experiences of people with dementia and their primary carers to understand what contributes to living well with dementia and enhances active life. <i>BMC Public Health</i> , 2018 , 18, 1214	4.1	27
283	Inflammatory mediators in the frontal lobe of patients with mixed and vascular dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 25, 278-86	2.6	26
282	Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. <i>Journal of Neurology</i> , 2009 , 256, 717-20	5.5	25
281	Dementia with Lewy bodies: clinical features and treatment. <i>Drugs and Aging</i> , 2001 , 18, 397-407	4.7	25
280	Multidisciplinary research priorities for the COVID-19 pandemic - Authors' reply. <i>Lancet Psychiatry</i> , 2020 , 7, e44-e45	23.3	24
279	Pharmacological profile of essential oils derived from <i>Lavandula angustifolia</i> and <i>Melissa officinalis</i> with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2008 , 60, 1515-22	4.8	24
278	Evaluating the effectiveness and cost-effectiveness of Dementia Care Mapping to enable person-centred care for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial. <i>Trials</i> , 2016 , 17, 300	2.8	24
277	Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM). <i>Clinical Interventions in Aging</i> , 2018 , 13, 935-946	4	24
276	Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design. <i>International Psychogeriatrics</i> , 2014 , 1-17	3.4	23
275	Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , 2014 , 29, 22-31	3.9	23
274	Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies. <i>Neuroscience Letters</i> , 2013 , 557 Pt B, 177-80	3.3	23
273	New Therapeutic Strategies for Lewy Body Dementias. <i>Current Neurology and Neuroscience Reports</i> , 2017 , 17, 68	6.6	23
272	New and emerging treatments for Alzheimer's disease. <i>Expert Opinion on Emerging Drugs</i> , 2012 , 17, 147-56	3.6	23
271	Increased neural progenitors in vascular dementia. <i>Neurobiology of Aging</i> , 2011 , 32, 2152-61	5.6	23
270	Implementing Remote Memory Clinics to Enhance Clinical Care During and After COVID-19. <i>Frontiers in Psychiatry</i> , 2020 , 11, 579934	5	23
269	Helping staff to implement psychosocial interventions in care homes: augmenting existing practices and meeting needs for support. <i>International Journal of Geriatric Psychiatry</i> , 2016 , 31, 284-93	3.9	23
268	Quantifying the association between computerised measures of attention and confusion assessment method defined delirium: a prospective study of older orthopaedic surgical patients, free of dementia. <i>International Journal of Geriatric Psychiatry</i> , 2008 , 23, 1253-60	3.9	22
267	Thalamic D2 receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia. <i>International Journal of Neuropsychopharmacology</i> , 2007 , 10, 231-44	5.8	22

266	The k variant of the butyrylcholinesterase gene is associated with reduced phosphorylation of tau in dementia patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005 , 19, 357-60	2.6	22
265	The Relationship between Post-Natal Depression, Somatization and Behaviour in Malaysian Women. <i>Transcultural Psychiatry</i> , 2001 , 38, 27-34	2.7	22
264	Drug repurposing for Alzheimer's disease based on transcriptional profiling of human iPSC-derived cortical neurons. <i>Translational Psychiatry</i> , 2019 , 9, 220	8.6	21
263	End of life treatment decisions in people with dementia: carers' views and the factors which influence them. <i>International Journal of Geriatric Psychiatry</i> , 2000 , 15, 1005-8	3.9	21
262	A prospective study of dementia with Lewy bodies. <i>Age and Ageing</i> , 1998 , 27, 631-6	3	21
261	(123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. <i>BMJ Open</i> , 2013 , 3,	3	20
260	Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with amyloid burden and synaptic deficits in Lewy body dementias. <i>Molecular Brain</i> , 2016 , 9, 84	4.5	20
259	Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 683-695	4.3	19
258	Familial occurrence of dementia and parkinsonism: a systematic review. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006 , 22, 288-95	2.6	19
257	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. <i>Health Technology Assessment</i> , 2017 , 21, 1-192	4.4	19
256	Associations of Awareness of Age-Related Change With Emotional and Physical Well-being: A Systematic Review and Meta-analysis. <i>Gerontologist</i> , <i>The</i> , 2020 , 60, e477-e490	5	19
255	Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's disease. <i>Translational Psychiatry</i> , 2019 , 9, 273	8.6	18
254	Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 101-10	4.3	18
253	A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD). <i>Journal of the American Medical Directors Association</i> , 2015 , 16, 316-22	5.9	18
252	Core and suggestive symptoms of dementia with lewy bodies cluster in persons with mild dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010 , 29, 317-24	2.6	18
251	Neuropsychological deficits in older stroke patients. <i>Annals of the New York Academy of Sciences</i> , 2002 , 977, 179-82	6.5	18
250	Cognitive decline in a prospectively studied group of stroke survivors, with a particular emphasis on the >75's. <i>Age and Ageing</i> , 2002 , 31 Suppl 3, 24-7	3	18
249	Trial of Pimavanserin in Dementia-Related Psychosis. <i>New England Journal of Medicine</i> , 2021 , 385, 309-319	59.2	18

248	Small vessel disease pathological changes in neurodegenerative and vascular dementias concomitant with autonomic dysfunction. <i>Brain Pathology</i> , 2020 , 30, 191-202	6	18
247	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018 , 33, 1769-1776	7	18
246	Increased Transforming Growth Factor β in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble A β Load. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 157-166	4.3	17
245	Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM). <i>Drugs and Aging</i> , 2018 , 35, 545-558	4.7	17
244	Improving Well-being and Health for People with Dementia (WHELD): study protocol for a randomised controlled trial. <i>Trials</i> , 2014 , 15, 284	2.8	17
243	Genetic associations of autopsy-confirmed vascular dementia subtypes. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011 , 31, 247-53	2.6	17
242	Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 1143-1156	4.3	17
241	Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. <i>American Journal of Geriatric Psychiatry</i> , 2020 , 28, 75-86	6.5	17
240	The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2018 , 18, 461-467	4.3	17
239	Analgesic treatments in people with dementia - how safe are they? A systematic review. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 511-522	4.1	16
238	Cerebrospinal Fluid Levels of sAPP β and sAPP α in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. <i>International Journal of Alzheimer's Disease</i> , 2011 , 2011, 495025	3.7	16
237	Neurogenic marker abnormalities in the hippocampus in dementia with Lewy bodies. <i>Hippocampus</i> , 2011 , 21, 1126-36	3.5	16
236	A pilot study examining associations between DYRK1A and β -synuclein dementias. <i>Neurodegenerative Diseases</i> , 2012 , 10, 229-31	2.3	16
235	The extended tau haplotype and the age of onset of dementia in Down syndrome. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 199-202	2.6	16
234	Apathy and Its Response to Antipsychotic Review and Nonpharmacological Interventions in People With Dementia Living in Nursing Homes: WHELD, a Factorial Cluster Randomized Controlled Trial. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 741-7	5.9	15
233	Correlation of entorhinal amyloid with memory in Alzheimer's and vascular but not Lewy body dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005 , 19, 57-60	2.6	15
232	Intraoperative Optimization of Both Depth of Anesthesia and Cerebral Oxygenation in Elderly Patients Undergoing Coronary Artery Bypass Graft Surgery-A Randomized Controlled Pilot Trial. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020 , 34, 1172-1181	2.1	15
231	The Incidence of Recorded Delirium Episodes Before and After Dementia Diagnosis: Differences Between Dementia With Lewy Bodies and Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2019 , 20, 604-609	5.9	15

230	Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. <i>Journal of prevention of Alzheimeris disease, The</i> , 2019 , 6, 27-33	3.8	15
229	What influences the sustainability of an effective psychosocial intervention for people with dementia living in care homes? A 9 to 12-month follow-up of the perceptions of staff in care homes involved in the WHELD randomised controlled trail. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 674-682	3.9	14
228	Medial temporal lobe atrophy and depressive symptoms in elderly patients with and without Alzheimer disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015 , 28, 40-8	3.8	14
227	Exploratory analysis of seven Alzheimer's disease genes: disease progression. <i>Neurobiology of Aging</i> , 2013 , 34, 1310.e1-7	5.6	14
226	alpha-Synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2010 , 22, 321-7	3.4	14
225	Anxiety disorder in dementia. <i>Irish Journal of Psychological Medicine</i> , 1994 , 11, 108-109	3	14
224	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. <i>Alzheimeris Research and Therapy</i> , 2021 , 13, 47	9	14
223	Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. <i>Journal of Alzheimeris Disease</i> , 2017 , 57, 373-386	4.3	13
222	Determining the association of the 5HTTLPR polymorphism with delusions and hallucinations in Lewy body dementias. <i>American Journal of Geriatric Psychiatry</i> , 2014 , 22, 580-6	6.5	13
221	Feasibility study of an optimised person-centred intervention to improve mental health and reduce antipsychotics amongst people with dementia in care homes: study protocol for a randomised controlled trial. <i>Trials</i> , 2013 , 14, 13	2.8	13
220	Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. <i>Trials</i> , 2013 , 14, 401	2.8	13
219	NOS3 gene rs1799983 polymorphism and incident dementia in elderly stroke survivors. <i>Neurobiology of Aging</i> , 2011 , 32, 554.e1-6	5.6	13
218	Preventing dementia. <i>Advances in Psychiatric Treatment</i> , 2005 , 11, 176-183		13
217	Placement of dementia sufferers in residential and nursing home care. <i>Age and Ageing</i> , 1998 , 27, 189-93		13
216	Dementia Care Mapping to reduce agitation in care home residents with dementia: the EPIC cluster RCT. <i>Health Technology Assessment</i> , 2020 , 24, 1-172	4.4	13
215	Improving the quality of life of care home residents with dementia: Cost-effectiveness of an optimized intervention for residents with clinically significant agitation in dementia. <i>Alzheimeris and Dementia</i> , 2019 , 15, 282-291	1.2	13
214	Reduced thermal sensitivity and increased opioidergic tone in the TASTPM mouse model of Alzheimer's disease. <i>Pain</i> , 2016 , 157, 2285-2296	8	12
213	The value of vitamin E as a treatment for Alzheimer's disease remains unproven despite functional improvement, due to a lack of established effect on cognition or other outcomes from RCTs. <i>Evidence-Based Medicine</i> , 2014 , 19, 140		12

212	Neuropsychiatric aspects of Alzheimer's disease. <i>Current Psychiatry Reports</i> , 1999 , 1, 49-60	9.1	12
211	Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. <i>F1000Research</i> , 2014 , 3, 108	3.6	12
210	Expression of neurogenic markers in Alzheimer's disease: a systematic review and metatranscriptional analysis. <i>Neurobiology of Aging</i> , 2019 , 76, 166-180	5.6	12
209	Investigating the relationship between age of onset of depressive disorder and cognitive function. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 38-46	3.9	12
208	Subtle deficits of attention after surgery: quantifying indicators of sub syndrome delirium. <i>International Journal of Geriatric Psychiatry</i> , 2010 , 25, 945-52	3.9	11
207	Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline. <i>Synapse</i> , 2007 , 61, 903-11	2.4	11
206	Homocysteine and post-stroke cognitive decline. <i>Age and Ageing</i> , 2007 , 36, 339-43	3	11
205	Definition and diagnosis of dementia with Lewy bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004 , 17 Suppl 1, 15-24	2.6	11
204	(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2018 , 15, 883-891	3	11
203	Neuropsychiatric Symptoms and Functional Decline in Alzheimer's Disease and Lewy Body Dementia. <i>Journal of the American Geriatrics Society</i> , 2020 , 68, 2257-2263	5.6	11
202	Antipsychotic Drug Use Is Not Associated With Long-Term Mortality Risk in Norwegian Nursing Home Patients. <i>Journal of the American Medical Directors Association</i> , 2016 , 17, 464.e1-7	5.9	11
201	Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 116	9	11
200	The cost of care homes for people with dementia in England: a modelling approach. <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 1466-1475	3.9	10
199	LIVE@Home.Path-innovating the clinical pathway for home-dwelling people with dementia and their caregivers: study protocol for a mixed-method, stepped-wedge, randomized controlled trial. <i>Trials</i> , 2020 , 21, 510	2.8	10
198	Person-centred care and care mapping in dementia. <i>Lancet Neurology</i> , 2009 , 8, 302-3	24.1	10
197	Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients. <i>Neuroscience Letters</i> , 2008 , 442, 297-9	3.3	10
196	Cognitive decline in Down syndrome. <i>Archives of Neurology</i> , 2003 , 60, 1024; author reply 1024		10
195	International relevance of two measures of awareness of age-related change (AARC). <i>BMC Geriatrics</i> , 2020 , 20, 359	4.1	10

194	Psychosis in Alzheimer's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2020 , 20, 57	6.6	10
193	An online investigation of the relationship between the frequency of word puzzle use and cognitive function in a large sample of older adults. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 921-931	3.9	10
192	Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 164-174	6	9
191	PERFECTED enhanced recovery (PERFECT-ER) care versus standard acute care for patients admitted to acute settings with hip fracture identified as experiencing confusion: study protocol for a feasibility cluster randomized controlled trial. <i>Trials</i> , 2017 , 18, 583	2.8	9
190	Feasibility of a staff training and support programme to improve pain assessment and management in people with dementia living in care homes. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 221-231	3.9	9
189	Ras-ERK-ETS inhibition alleviates neuronal mitochondrial dysfunction by reprogramming mitochondrial retrograde signaling. <i>PLoS Genetics</i> , 2018 , 14, e1007567	6	9
188	Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 728-730	5.5	9
187	Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture. <i>Journal of Neural Transmission</i> , 2012 , 119, 1467-76	4.3	9
186	Mild cognitive impairment and vascular cognitive impairment in stroke patients. <i>International Psychogeriatrics</i> , 2003 , 15 Suppl 1, 123-6	3.4	9
185	Agitation and impulsivity in mid and late life as possible risk markers for incident dementia. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , 2020 , 6, e12016	6	9
184	Cross-sectional association between objective cognitive performance and perceived age-related gains and losses in cognition. <i>International Psychogeriatrics</i> , 2021 , 33, 727-741	3.4	9
183	Associations between ZnT3, tau pathology, agitation, and delusions in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018 , 33, 1146-1152	3.9	9
182	Emerging amyloid and tau targeting treatments for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 697-711	4.3	8
181	Alzheimer disease and stroke: Cognitive and neuroimaging predictors of AD and stroke. <i>Nature Reviews Neurology</i> , 2013 , 9, 605-6	15	8
180	Analysis of neuron-specific enolase and S100B as biomarkers of cognitive decline following surgery in older people. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012 , 34, 307-11	2.6	8
179	VARIABLES WHICH DISTINGUISH PATIENTS FULFILLING CLINICAL CRITERIA FOR DEMENTIA WITH LEWY BODIES FROM THOSE WITH ALZHEIMER'S DISEASE 1997 , 12, 314-318		8
178	Psychiatric sequelae of MDMA (ecstasy) and related drugs. <i>Irish Journal of Psychological Medicine</i> , 1994 , 11, 132-133	3	8
177	Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. <i>Parkinsonism and Related Disorders</i> , 2020 , 77, 100-106	3.6	8

176	Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>European Journal of Epidemiology</i> , 2021 , 36, 89-101	12.1	8
175	Potentially inappropriate prescribing in dementia, multi-morbidity and incidence of adverse health outcomes. <i>Age and Ageing</i> , 2021 , 50, 457-464	3	8
174	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimeris and Dementia</i> , 2015 , 11, 455-61	1.2	7
173	Alcohol and dementia: a complex relationship with potential for dementia prevention. <i>Lancet Public Health, The</i> , 2018 , 3, e103-e104	22.4	7
172	Mitochondrial Translocase of the Outer Membrane Alterations May Underlie Dysfunctional Oxidative Phosphorylation in Alzheimer's Disease. <i>Journal of Alzheimeris Disease</i> , 2018 , 61, 793-801	4.3	7
171	CSF Synuclein as a diagnostic biomarker for Parkinson disease and related dementias. <i>Neurology</i> , 2010 , 75, 1760-1	6.5	7
170	Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2021 , 398, 1487-1497	4.0	7
169	Cost-Effectiveness of Dementia Care Mapping in Care-Home Settings: Evaluation of a Randomised Controlled Trial. <i>Applied Health Economics and Health Policy</i> , 2020 , 18, 237-247	3.4	7
168	Isoform-specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias. <i>Brain Pathology</i> , 2021 , 31, 253-266	6	7
167	Measuring the Effectiveness of Safety Warnings on the Risk of Stroke in Older Antipsychotic Users: A Nationwide Cohort Study in Two Large Electronic Medical Records Databases in the United Kingdom and Italy. <i>Drug Safety</i> , 2019 , 42, 1471-1485	5.1	6
166	Liraglutide and semaglutide: Pooled post hoc analysis to evaluate risk of dementia in patients with type 2 diabetes. <i>Alzheimeris and Dementia</i> , 2020 , 16, e042909	1.2	6
165	Effectiveness of Dementia Care Mapping to reduce agitation in care home residents with dementia: an open-cohort cluster randomised controlled trial. <i>Aging and Mental Health</i> , 2021 , 25, 1410-1423	3.5	6
164	Importance of Proactive Treatment of Depression in Lewy Body Dementias: The Impact on Hippocampal Neurogenesis and Cognition in a Post-Mortem Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017 , 44, 283-293	2.6	6
163	Cognitive impairment in studies of 5HTTLPR and psychosis in Alzheimer's disease: a systematic review. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013 , 35, 155-64	2.6	6
162	An Intron 7 Polymorphism in APP Affects the Age of Onset of Dementia in Down Syndrome. <i>International Journal of Alzheimeris Disease</i> , 2010 , 2011, 929102	3.7	6
161	Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020 , 7, 1-62	1.7	6
160	Improving mental health and reducing antipsychotic use in people with dementia in care homes: the WHELD research programme including two RCTs. <i>Programme Grants for Applied Research</i> , 2020 , 8, 1-98	1.5	6
159	The cross-sectional relationship between pain and awareness of age-related changes. <i>British Journal of Pain</i> , 2021 , 15, 335-344	2.1	6

158	Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019 , 67, 303-313	4.3	6
157	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. <i>BMJ Open</i> , 2019 , 9, e024498	3	5
156	A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment of subcortical ischaemic vascular dementia (AFFECT): study protocol. <i>Trials</i> , 2016 , 17, 324	2.8	5
155	Baseline characteristics, analysis plan and report on feasibility for the Prevention Of Decline in Cognition After Stroke Trial (PODCAST). <i>Trials</i> , 2015 , 16, 509	2.8	5
154	Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease. <i>Expert Review of Clinical Pharmacology</i> , 2014 , 7, 779-86	3.8	5
153	No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. <i>Neuroscience Letters</i> , 2012 , 531, 1-4	3.3	5
152	Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid Aβ40 and tau in patients with intractable unipolar depression. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 1283-91	3.9	5
151	Is apolipoprotein e4 associated with cognitive decline in depression?. <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16, 436-7	3.9	5
150	Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities.. <i>Nature Reviews Neurology</i> , 2022 ,	15	5
149	Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study. <i>BMC Medicine</i> , 2020 , 18, 351	11.4	5
148	Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis. <i>International Journal of Geriatric Psychiatry</i> , 2020 , 35, 1402-1408	3.9	5
147	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. <i>Molecular Psychiatry</i> , 2021 ,	15.1	5
146	Striatal Dopaminergic Deficit and Sleep in Idiopathic Rapid Eye Movement Behaviour Disorder: An Explorative Study. <i>Nature and Science of Sleep</i> , 2021 , 13, 1-9	3.6	5
145	Predictors of changes after reasoning training in healthy adults. <i>Brain and Behavior</i> , 2020 , 10, e01861	3.4	4
144	Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An PET Study With Neuropathological Comparison. <i>Frontiers in Neurology</i> , 2020 , 11, 541377	4.1	4
143	Role of the extended MAPT haplotype in the worsening of psychotic symptoms and treatment response in Alzheimer disease. <i>Journal of the American Medical Directors Association</i> , 2014 , 15, 934-7	5.9	4
142	Dementia: challenges and promising developments. <i>Lancet Neurology</i> , 2011 , 10, 7-9	24.1	4
141	Antipsychotics in patients with Alzheimer's disease--what is their clinical value?. <i>Nature Clinical Practice Neurology</i> , 2007 , 3, 248-9		4

140	Factors influencing general practitioner referral to a child psychiatric service. <i>Irish Journal of Psychological Medicine</i> , 1993 , 10, 144-147	3	4
139	Profile of Mild Behavioral Impairment and Factor Structure of the Mild Behavioral Impairment Checklist in Cognitively Normal Older Adults		4
138	Psychosis-associated DNA methylomic variation in Alzheimer's disease cortex. <i>Neurobiology of Aging</i> , 2020 , 89, 83-88	5.6	4
137	Transcription-based drug repurposing for COVID-19. <i>Virus Research</i> , 2020 , 290, 198176	6.4	4
136	Relationship between self-perceptions of aging and 'living well' among people with mild-to-moderate dementia: Findings from the ideal programme. <i>Archives of Gerontology and Geriatrics</i> , 2021 , 94, 104328	4	4
135	Sex differences in the association of mild behavioral impairment with cognitive aging		4
134	The relationship between the frequency of number-puzzle use and baseline cognitive function in a large online sample of adults aged 50 and over. <i>International Journal of Geriatric Psychiatry</i> , 2019 , 34, 932-940	3.9	4
133	Executive function but not episodic memory decline associated with visual hallucinations in Parkinson's disease. <i>Journal of Neuropsychology</i> , 2020 , 14, 85-97	2.6	4
132	The Mental and Physical Health of Older Adults With a Genetic Predisposition for Autism. <i>Autism Research</i> , 2020 , 13, 641-654	5.1	4
131	The relationship between antipsychotic treatment and quality of life for patients with dementia living in residential and nursing home care facilities. <i>Journal of Clinical Psychiatry</i> , 2004 , 65 Suppl 11, 23-8	4.6	4
130	Lower cognitive baseline scores predict cognitive training success after 6 months in healthy older adults: Results of an online RCT. <i>International Journal of Geriatric Psychiatry</i> , 2020 , 35, 1000-1008	3.9	3
129	Reducing psychotropic drug use in people with dementia living in nursing homes. <i>International Psychogeriatrics</i> , 2020 , 32, 291-294	3.4	3
128	Dynamin protein in stroke and vascular dementia. <i>Neuroscience Letters</i> , 2014 , 563, 118-22	3.3	3
127	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. <i>Journal of Neural Transmission</i> , 2014 , 121, 71-8	4.3	3
126	Melissa aromatherapy as safe and effective treatment. <i>Nursing and Residential Care</i> , 2003 , 5, 80-82	0.1	3
125	Psychiatric issues in non-Alzheimer dementias. <i>Clinical Neuroscience Research</i> , 2004 , 3, 397-412		3
124	Exploring awareness of age-related changes among over 50s in the UK: findings from the PROTECT study. <i>International Psychogeriatrics</i> , 2021 , 1-15	3.4	3
123	Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson's Disease Dementia. <i>Journal of Parkinson's Disease</i> , 2016 , 6, 733-739	5.3	3

122	Gender/Sex Differences in the Association of Mild Behavioral Impairment with Cognitive Aging. <i>Journal of Alzheimeris Disease</i> , 2022 , 1-11	4.3	3
121	The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review □ CORRIGENDUM. <i>International Psychogeriatrics</i> , 2014 , 26, 1099-1099	3.4	2
120	Information provision services in dementia care. <i>International Journal of Older People Nursing</i> , 2011 , 6, 217-26	2.3	2
119	Clinical management of dementia. <i>Psychiatry (Abingdon, England)</i> , 2008 , 7, 88-93		2
118	Alzheimer's disease □ vascular dementia?. <i>Reviews in Clinical Gerontology</i> , 2003 , 13,		2
117	Prevalence of abnormal eating amongst elderly people in residential care. <i>International Journal of Geriatric Psychiatry</i> , 2000 , 15, 283-4	3.9	2
116	The Charles Bonnet Syndrome associated with vascular pathology □ classical presentation with a very atypical course. <i>Irish Journal of Psychological Medicine</i> , 1991 , 8, 44-45	3	2
115	The phenomena of Bingeing □ <i>Irish Journal of Psychological Medicine</i> , 1992 , 9, 61-62	3	2
114	Predictors of activities of daily living in heathy older adults: Who benefits most from online cognitive training?. <i>Brain and Behavior</i> , 2021 , 11, e2388	3.4	2
113	Online Education and Cognitive Behavior Therapy Improve Dementia Caregivers' Mental Health: A Randomized Trial. <i>Journal of the American Medical Directors Association</i> , 2021 , 22, 1403-1409.e1	5.9	2
112	Psychiatric and neuropsychiatric syndromes and COVID-19. <i>Lancet Psychiatry,the</i> , 2020 , 7, 663-664	23.3	2
111	The Mental and Physical Health Profiles of Older Adults Who Endorse Elevated Autistic Traits. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021 , 76, 1726-1737	4.6	2
110	Whole transcriptome in silico screening implicates cardiovascular and infectious disease in the mechanism of action underlying atypical antipsychotic side effects. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , 2020 , 6, e12078	6	2
109	The impact of auditory hallucinations on "living well" with dementia: Findings from the IDEAL programme. <i>International Journal of Geriatric Psychiatry</i> , 2021 , 36, 1370-1377	3.9	2
108	Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients. <i>Parkinsonism and Related Disorders</i> , 2021 , 87, 25-31	3.6	2
107	Non-benzodiazepine hypnotic use for sleep disturbance in people aged over 55 years living with dementia: a series of cohort studies. <i>Health Technology Assessment</i> , 2021 , 25, 1-202	4.4	2
106	P3-554: PROFILE OF MILD BEHAVIOURAL IMPAIRMENT IN A POPULATION-BASED SAMPLE OF ADULTS AGED 50 AND OVER: INITIAL FINDINGS FROM THE PROTECT STUDY 2018 , 14, P1335-P1335		2
105	P4-017: CLINICAL TRIAL PIPELINES FOR ALZHEIMER'S DISEASE POSE CHALLENGES FOR FUTURE EFFECTIVE TREATMENT AND THERAPIES 2018 , 14, P1439-P1439		2

104	P3-023: BEYOND ANTIPSYCHOTICS: EXPLORING EFFICACY AND HARMS OF Z-DRUGS FOR SLEEP DISTURBANCE ON THE PROGRESSION OF KEY DEMENTIA OUTCOMES 2018 , 14, P1072-P1073		2
103	Historical landmarks in dementia with Lewy bodies. <i>Lancet Neurology, The</i> , 2017 , 16, 348	24.1	1
102	Linking electronic dementia care records to national inpatient data in dementia with Lewy bodies: Frequency, duration and cost implications of hospitalization and recording of delirium episodes. <i>Alzheimeris and Dementia</i> , 2020 , 16, e039139	1.2	1
101	FLAME: A computerized neuropsychological composite for trials in early dementia. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12098	5.2	1
100	Evidence-based prevention and treatment of dementia - Authors' reply. <i>Lancet Neurology, The</i> , 2016 , 15, 1007-8	24.1	1
99	Alzheimer's Disease Progression in the 5BAD Mouse Captured with a Multiplex Gene Expression Array. <i>Journal of Alzheimeris Disease</i> , 2019 , 72, 1177-1191	4.3	1
98	[P1099]: AN EVALUATION OF PREDICTORS AND COGNITIVE DECLINE ASSOCIATED WITH PERSISTENT AND TRANSIENT PSYCHOTIC SYMPTOMS IN ALZHEIMER'S DISEASE 2017 , 13, P367-P367		1
97	[P1064]: RISK AND DURATION OF HOSPITALIZATION IN DEMENTIA WITH LEWY BODIES 2017 , 13, P510-P511		1
96	A small proportion of people with dementia and neuropsychiatric symptoms experience clinically significant worsening when antidepressants are discontinued. <i>Evidence-Based Medicine</i> , 2013 , 18, 27-8		1
95	Video decision support affects patients' care choices in dementia care planning. <i>Evidence-Based Mental Health</i> , 2010 , 13, 12	11.1	1
94	Effectiveness of collaborative care for elderly adults with Alzheimer's disease in primary care. <i>Lancet Neurology, The</i> , 2006 , 5, 644-5	24.1	1
93	Current perspectives in dementia with Lewy bodies. <i>Aging Health</i> , 2006 , 2, 461-472		1
92	Cholinesterase inhibitors in the treatment of dementia. <i>International Journal of Geriatric Psychiatry</i> , 2003 , 18, 458-9	3.9	1
91	Neurochemistry of severe dementia. <i>Reviews in Clinical Gerontology</i> , 2005 , 15, 105-123		1
90	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts.. <i>British Journal of Psychiatry</i> , 2022 , 1-10	5.4	1
89	Differences in awareness of positive and negative age-related changes accounting for variability in health outcomes. <i>European Journal of Ageing</i> , 2021 , 1	3.6	1
88	Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias. <i>Neurochemistry International</i> , 2021 , 152, 105251-4	4.4	1
87	Risky drinking and cognitive impairment in community residents aged 50 and over. <i>Aging and Mental Health</i> , 2021 , 1-8	3.5	1

86	Genome-Wide Association Identifies the First Risk Loci for Psychosis in Alzheimer Disease		1
85	Diagnosing Dementia-Related Psychosis: Using Tools and Communicating With Patients and Caregivers. <i>Journal of Clinical Psychiatry</i> , 2020 , 82,	4.6	1
84	Association between schizophrenia polygenic score and psychotic symptoms in Alzheimer's disease: meta-analysis of 11 cohort studies		1
83	Associations of subjective cognitive and memory decline with depression, anxiety, and two-year change in objectively-assessed global cognition and memory. <i>Aging, Neuropsychology, and Cognition</i> , 2021 , 1-27	2.1	1
82	Dispersed Sleep Microstates and Associated Structural Changes in GBA1 Mouse: Relevance to Rapid Eye Movement Behavior Disorder		1
81	In vivo multi-parametric manganese-enhanced MRI for detecting amyloid plaques in rodent models of Alzheimer's disease. <i>Scientific Reports</i> , 2021 , 11, 12419	4.9	1
80	P4-622: DEMENTIA HOSPITAL CARE RESEARCH PROGRAMME: PERI-OPERATIVE ENHANCED RECOVERY HIP FRACTURE CARE OF PATIENTS WITH DEMENTIA (PERFECTED) CLUSTER RANDOMISED CONTROL TRIAL RESULTS 2019 , 15, P1565-P1565		1
79	Healthy adjustment for new residents with dementia using SettleIN: A feasibility study in UK care homes. <i>Dementia</i> , 2020 , 19, 1811-1828	3	1
78	P1-658: REPEATED COGNITIVE TESTING REDUCES SAMPLE SIZE NECESSARY TO DETECT CLINICALLY RELEVANT EFFECTS 2018 , 14, P595-P595		1
77	O4-03-06: A RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF AN E-LEARNING INTERVENTION BASED ON THE IMPROVING WELL-BEING AND HEALTH FOR PEOPLE WITH DEMENTIA (WHELD) PERSON-CENTRED CARE TRAINING PROGRAMME 2018 , 14, P1406-P1406		1
76	Reply: Functional cognitive disorder: dementia's blind spot. <i>Brain</i> , 2021 , 144, e73	11.2	1
75	Computerized neuropsychological tests undertaken on digital platforms are cost effective, achieve high engagement, distinguish and are highly sensitive to longitudinal change: Data from the PROTECT and GBIT studies. <i>Alzheimeris and Dementia</i> , 2020 , 16, e041122	1.2	0
74	Higher perceived age-related gains and losses relate to lower objective cognitive scores. <i>Alzheimeris and Dementia</i> , 2020 , 16, e043999	1.2	0
73	Impact of psychosis on quality of life and well-being in dementia. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045871	1.2	0
72	Atypical antipsychotics fail to improve functioning or quality of life in people with Alzheimer's disease. <i>Evidence-Based Mental Health</i> , 2009 , 12, 20	11.1	0
71	Non-Alzheimer dementias. <i>Current Opinion in Psychiatry</i> , 2000 , 13, 409-414	4.9	0
70	Christmas census at a district general hospital psychiatric unit. <i>Irish Journal of Psychological Medicine</i> , 1991 , 8, 46-47	3	0
69	Cross-Sectional and Longitudinal Associations between Subjective Sleep Difficulties and Self-Perceptions of Aging. <i>Behavioral Sleep Medicine</i> , 2021 , 1-30	4.2	0

68	Effects of Purified Anthocyanins in People at Risk for Dementia: Study Protocol for a Phase II Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2020 , 11, 916	4.1	o
67	Next-Generation RNA-Sequencing of Serum Small Extracellular Vesicles Discovers Potential Diagnostic Biomarkers for Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2021 , 29, 573-584	6.5	o
66	What does feeling younger or older than one's chronological age mean to men and women? Qualitative and quantitative findings from the PROTECT study. <i>Psychology and Health</i> , 2021 , 1-24	2.9	o
65	Investigating the effects of impairment in non-verbal communication on neuropsychiatric symptoms and quality of life of people living with dementia. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , 2021 , 7, e12172	6	o
64	PERFECTED enhanced recovery pathway (PERFECT-ER) versus standard acute hospital care for people after hip fracture surgery who have cognitive impairment: a feasibility cluster randomised controlled trial.. <i>BMJ Open</i> , 2022 , 12, e055267	3	o
63	Relevance of sleep and associated structural changes in GBA1 mouse to human rapid eye movement behavior disorder.. <i>Scientific Reports</i> , 2022 , 12, 7973	4.9	o
62	Are subtypes of affective symptoms differentially associated with change in cognition over time: A latent class analysis.. <i>Journal of Affective Disorders</i> , 2022 , 309, 437-445	6.6	o
61	A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey. <i>Frontiers in Psychiatry</i> , 2020 , 11, 602480	5	
60	Depression and anxiety are associated with decline in executive function over two years in adults 50 and over. <i>Alzheimeris and Dementia</i> , 2020 , 16, e036342	1.2	
59	Antipsychotic use in dementia: The relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>Alzheimeris and Dementia</i> , 2020 , 16, e039145	1.2	
58	Relationship between genetic risk for Alzheimer's, cognition and neuropsychiatric symptoms: A case study of DNA sampling and analysis through digital platform cohort studies. <i>Alzheimeris and Dementia</i> , 2020 , 16, e040237	1.2	
57	In-silico high throughput whole transcriptome screening implicates cardiovascular disease and the immune system in the mechanism of action underlying adverse effects of atypical antipsychotics. <i>Alzheimeris and Dementia</i> , 2020 , 16, e043586	1.2	
56	Neuropsychiatric symptoms and cognitive decline: Trait or state effects?. <i>Alzheimeris and Dementia</i> , 2020 , 16, e043789	1.2	
55	Behavioural symptoms in Alzheimer's disease are associated with white matter lesions (WML) volume and are independent of atrophy and hypometabolism. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045223	1.2	
54	HARMONY: Response to pimavanserin in the 12-week, open-label treatment phase. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045431	1.2	
53	Stroke, genetic risk and incidence of dementia. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045870	1.2	
52	Influence of cerebral glucose metabolic rate on cognitive function in Alzheimer's subjects. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045899	1.2	
51	Genetic risk, education and incidence of dementia. <i>Alzheimeris and Dementia</i> , 2020 , 16, e045903	1.2	

- 50 Assessing the relationship between cognitive dysfunction and brain atrophy in Alzheimer's disease. *Alzheimeris and Dementia*, **2020**, 16, e046004 1.2
- 49 Relationship between spectral analysis, SUV and SUV Pons ratio as a measure of cerebral glucose metabolic rate in Alzheimer's disease. *Alzheimeris and Dementia*, **2020**, 16, e046068 1.2
- 48 [F10101]: IMPACT OF WHELD INTERVENTION ON NEUROPSYCHIATRIC SYMPTOMS, ANTIPSYCHOTIC USE AND QUALITY OF LIFE IN PEOPLE WITH DEMENTIA LIVING IN NURSING HOMES: A CLUSTER-RANDOMIZED TRIAL **2017**, 13, P171
- 47 Dextromethorphan and quinidine are suitable for off-label short-term treatment of agitation in people with Alzheimer's disease following first-line non-drug approaches. *Evidence-Based Medicine*, **2016**, 21, 25
- 46 Commentary: Opportunities for Combination Trials. *journal of prevention of Alzheimeris disease, The*, **2019**, 6, 177-178 3.8
- 45 Cognitive Impairment and the Dementias **2014**, 181-286
- 44 [P1B09]: PREVALENCE AND CO-MORBIDITY OF APATHY AND DEPRESSION IN ALZHEIMER'S DISEASE **2017**, 13, P371-P372
- 43 [P1035]: RELATIONSHIP BETWEEN PATHOLOGY SCORES, CLINICAL DATA AND EXPRESSION LEVELS OF PROTEASOME SUB-UNITS IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS **2017**, 13, P333-P334
- 42 [P2B81]: THE RELATIONSHIP BETWEEN THE FREQUENCY OF WORD PUZZLE USE AND COGNITIVE FUNCTION IN A LARGE SAMPLE OF ADULTS AGED 50 TO 96 YEARS **2017**, 13, P869-P870
- 41 [P3B82]: CAN INCREASING THE DIFFICULTY OF A NEUROGENESIS-SENSITIVE TASK ENHANCE ITS SENSITIVITY TO DETECTING AGE-RELATED DECLINES IN VOLUNTEERS AGED 50 TO 96? **2017**, 13, P1204
- 40 [P1B62]: EPIDEMIOLOGY OF PAIN IN PEOPLE WITH DEMENTIA LIVING IN CARE HOMES: LONGITUDINAL COURSE, PREVALENCE AND TREATMENT IMPLICATIONS **2017**, 13, P509-P510
- 39 [P1B99]: ONLINE COGNITIVE TRAINING INCREASES NEUROGENESIS AND IMPROVES COGNITIVE PERFORMANCE IN ADULTS OVER 50 **2017**, 13, P525-P525
- 38 [P1B12]: THE RELATIONSHIP BETWEEN SELF-REPORTED MONTHLY PHYSICAL EXERCISE FREQUENCY AND COGNITIVE FUNCTION **2017**, 13, P531-P531
- 37 [P1B14]: THE ASSOCIATION BETWEEN COGNITIVE FUNCTION AND ACTIVITIES OF DAILY LIVING IN HEALTHY ADULTS AGED 50 AND OVER **2017**, 13, P532-P532
- 36 [P2004]: RPT6, 20S K AND B PROTEASOME SUBUNIT LEVELS AND ASSOCIATION WITH COGNITIVE DECLINE IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS **2017**, 13, P684-P684
- 35 [P3B63]: RISK FACTORS FOR DEMENTIA AND COGNITIVE FUNCTION IN HEALTHY ADULTS **2017**, 13, P1194-P1195
- 34 Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies - ADDENDUM. *International Psychogeriatrics*, **2014**, 1 3.4
- 33 Safety and Efficacy of Memantine Extended-Release in the Management of Alzheimer's Disease. *Clinical Medicine Insights Therapeutics*, **2013**, 5, CMT.S7794 0

- 32 Management of agitation and aggression: controversies and possible solutions **2012**, 68-79
- 31 Time to discontinuation similar for atypical antipsychotic drugs and placebo in people with Alzheimer's disease. *Evidence-Based Mental Health*, **2007**, 10, 58 11.1
- 30 Dementia with Lewy Bodies and Parkinson's Disease Dementia Editors: JOHN O'BRIEN, IAN MCKEITH, DAVID AMES AND EDMOND CHIU, London, Taylor and Francis, 2005, £75.00 Hard cover, pp. 264 ISBN 1 8418 4491 8. *International Psychogeriatrics*, **2006**, 18, 763-764 3.4
- 29 Clinical management of dementia. *Psychiatry (Abingdon, England)*, **2004**, 3, 27-32
- 28 Antidepressants in the elderly: a review. *Expert Opinion on Investigational Drugs*, **1999**, 8, 51-63 5.9
- 27 ABC of Monitoring Drug Therapy. By J. K. Aronson, M. Hardman and D. J. M. Reynolds London: BMJ. 1993. 38 pp. £6.95.. *British Journal of Psychiatry*, **1994**, 165, 283-283 5.4
- 26 Cognitive and emotional improvement in a group of dementia patients. *Acta Psychiatrica Scandinavica*, **1990**, 81, 96 6.5
- 25 Sexual abuse: Crisis and response to counselling. *Journal of Forensic Psychiatry Psychology*, **1991**, 2, 211-216
- 24 Pimavanserin and dementia-related psychosis.. *Lancet Neurology*, **2022**, 21, 114-115 24.1
- 23 Cholinergic and Serotonergic Systems in Severe Dementia 21-31
- 22 NHS Continuing Care **2010**, 759-765
- 21 Can Intraoperative Optimization of Both Anesthetic Depth and Cerebral Oxygenation Really Result in Different Influences on Cognitive Function and Delirium in Elderly Patients Undergoing Cardiac Surgery? Response to Letter to the Editor by Xue et al. *Journal of Cardiothoracic and Vascular Anesthesia*, **2021**, 35, 1006-1007 2.1
- 20 REPRINTED WITH PERMISSION OF IASP [PAIN 162 (2021) 999-1006: Pain in the neurodegenerating brain: insights into pharmacotherapy for Alzheimer disease and Parkinson disease. *BMJ* **2021**, 22, 46-55 0
- 19 Better together for better dementia research and care. *Lancet Psychiatry*, **2016**, 3, 503-4 23.3
- 18 P4-627: NO IMPROVEMENT IN NURSING HOME CARE FOR PEOPLE WITH DEMENTIA SINCE THE MILLENNIUM **2019**, 15, P1568-P1568
- 17 P4-018: IMPAIRED CHRONIC PAIN-LIKE BEHAVIOUR AND DISRUPTION OF OPIOIDERGIC SYSTEM IN TASTPM MODEL OF ALZHEIMER'S DISEASE **2018**, 14, P1439-P1440
- 16 F3-03-01: EFFICACY, COST-EFFECTIVENESS AND SUSTAINED ENGAGEMENT OF THE IMPROVING WELL-BEING AND HEALTH FOR PEOPLE WITH DEMENTIA (WHELD) PERSON-CENTERED CARE TRAINING PROGRAMME **2018**, 14, P999-P999
- 15 P3-225: PERIPHERAL INSULIN RESISTANCE DOES NOT CORRELATE WITH CEREBRAL GLUCOSE METABOLIC RATE IN NON-DIABETIC ALZHEIMER'S PATIENTS **2018**, 14, P1157-P1158

- 14 P1-523: THE RELATIONSHIP BETWEEN THE MILD BEHAVIOURAL IMPAIRMENT CHECKLIST (MBI-C) TOTAL SCORE AND CORE ASPECTS OF COGNITIVE FUNCTION IN OLDER ADULTS **2018**, 14, P532-P532
- 13 P2-010: INVOLVEMENT OF ELEVATED NEUROINFLAMMATION IN KEY REGIONS OF THE PAIN PATHWAY IN NOCICEPTIVE PROCESSING IN ALZHEIMER'S DISEASE **2018**, 14, P668-P668
- 12 P1-151: GENETIC OVERLAP BETWEEN PSYCHOTIC SYMPTOMS ACROSS THE LIFESPAN: FINDINGS FROM SCHIZOPHRENIA, COGNITIVELY NORMAL OLDER ADULTS AND ALZHEIMER'S DISEASE **2018**, 14, P335-P335
- 11 P2-483: DEPRESSION IS ASSOCIATED WITH IMPAIRMENT IN COGNITIVE FUNCTION IN ADULTS AGED 50 AND OVER **2018**, 14, P914-P914
- 10 P4-026: A TRIAGE SYSTEM FOR IDENTIFYING CANDIDATE COMPOUNDS FOR REPURPOSING AS POTENTIAL THERAPEUTICS FOR AD (GATT) **2018**, 14, P1443-P1443
- 9 O3-08-06: RESULTS OF A PRAGMATIC, CLUSTER RANDOMISED, CONTROLLED TRIAL OF THE EFFECTIVENESS AND COST-EFFECTIVENESS OF DEMENTIA CARE MAPPING (DCM) IN UK CARE HOMES (DCM EPIC TRIAL) **2018**, 14, P1035-P1035
- 8 O5-07-05: HEALTH ECONOMIC ANALYSIS OF THE IMPROVING WELL-BEING AND HEALTH FOR PEOPLE WITH DEMENTIA (WHELD) PERSON-CENTRED CARE TRAINING FOR THE TREATMENT OF AGITATION IN PEOPLE WITH DEMENTIA: A CLUSTER RANDOMIZED CONTROLLED TRIAL **2018**, 14, P1663-P1664
- 7 F4-03-04: A SUMMARY OF THE RATIONALE AND DESIGN OF THE HARMONY STUDY: A PHASE 3 STUDY TO EVALUATE PIMAVANSERIN FOR THE TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH DEMENTIA-RELATED PSYCHOSIS **2018**, 14, P1387-P1387
- 6 P3-002: PIMAVANSERIN IN ALZHEIMER'S DISEASE PSYCHOSIS: SUBGROUP ANALYSIS OF THE MORE SEVERE POPULATION **2018**, 14, P1062-P1062
- 5 P2-143: PSYCHOSIS-ASSOCIATED EPIGENETIC VARIATION IN PATIENTS WITH ALZHEIMER'S DISEASE ACROSS CORTICAL BRAIN REGIONS **2018**, 14, P723-P723
- 4 P3-003: IDENTIFYING ENRICHMENT FACTORS THAT PREDICT ALZHEIMER'S DISEASE PROGRESSION: AN ANALYSIS OF THREE RANDOMIZED, CONTROLLED TRIALS **2018**, 14, P1062-P1063
- 3 P3-001: A RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO INVESTIGATE SAFETY OF BUPRENORPHINE TRANSDERMAL SYSTEM FOR PAIN MANAGEMENT IN PEOPLE WITH DEMENTIA **2018**, 14, P1062-P1062
- 2 Repurposed Agents in Alzheimer's Disease Drug Development **2022**, 54-61
- 1 Development and assessment of a brief screening tool for psychosis in dementia.. *Alzheimeris and Dementia*, **2021**, 17 Suppl 8, e057766 1.2